Is DexCom Stock Cheaper Now That Its Multiple Has Fallen?
For questions about this article or underlying research, email help@trefis.com.
A lower price-to-earnings multiple, what investors pay for each dollar of profit, usually signals a cheaper stock. DexCom (DXCM) has seen its multiple fall a long way, dropping from 95.7 three years ago to 30.2 at the latest close. Does a fall that steep mean DexCom stock now costs you less than it did?
DexCom Stock Dipped While Its Multiple Fell
DexCom’s share price fell 14.3% from the end of September 2023 to its latest close in November 2026, before dividends. Over the same years the multiple fell far more steeply, so most of its fall did not come from the share price.
How Much Has DexCom’s Profit Grown?
DexCom’s profit over the latest twelve months was $0.991 billion, compared with $0.377 billion three years earlier. Profit is now 2.6 times what it was.
| Twelve months to | Net income | Change in a year | Price-to-earnings |
|---|---|---|---|
| Sep 30, 2021 | $0.577 billion | +149.8% | 91.7 |
| Sep 30, 2022 | $0.244 billion | -57.7% | 128.6 |
| Sep 30, 2023 | $0.377 billion | +54.4% | 95.7 |
| Sep 30, 2024 | $0.681 billion | +80.6% | 38.8 |
| Sep 30, 2025 | $0.721 billion | +5.9% | 36.5 |
| Sep 30, 2026 | $0.991 billion | +37.5% | 32.6 |
| Sep 30, 2026 (at the share price of Nov 10, 2026) | $0.991 billion | +37.5% | 30.2 |
Net income is the reported total for the twelve months ending on the date shown. Change in a year is that net income against the twelve months before. Each price-to-earnings multiple is the market value at the calendar quarter end paired with those twelve months, over that net income; the last row uses the share price of Nov 10, 2026.
DexCom sells sensors that track glucose for people with diabetes, including its G7 15 Day system, and management said on the October 29 call that its largest U.S. share gains came from customers with type 2 diabetes. Sales grew every year over the three years, and DexCom kept more of each sale: its operating margin was 24.0% in the latest twelve months, against 14.9% three years earlier.
Does A Lower Multiple Make DexCom Cheaper?
So the multiple peaked when there was far less profit. Twelve-month profit had just fallen to $0.217 billion from $0.577 billion a quarter earlier, while DexCom’s market value barely moved. That is the curve a growing company follows: the multiple is highest while profit is small, and it comes down as the profit arrives. A buyer today does pay less for each dollar of profit than a buyer three years ago. But that earlier buyer was paying in advance for growth that has since happened. So the stock is cheaper on each dollar of profit, mostly because profit grew rather than because the share price fell. Even so, that buyer’s shares are lower now, so the growth that arrived did not hold up the price paid.
Where Is DexCom On That Curve Now?
DexCom’s profit grew 37.5% in the latest twelve months, compared with 5.9% in the twelve months before. Sales rose 13.0% over the same twelve months, so profit grew faster than sales. In the third quarter of 2026 alone, however, profit was 3.2% below the same quarter a year earlier. Operating profit rose to $0.327 billion from $0.243 billion, though. The year-earlier quarter’s net income had been lifted above its operating profit.
Does This Mean You Should Act On DXCM?
Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.
Spot an error or want more like this? Tell us in 10 seconds.